Genprex, Inc. Share-based Payment Arrangement, Accelerated Cost
Genprex, Inc. (GNPX) reported Share-based Payment Arrangement, Accelerated Cost of $1.50 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2020-08-11
- Genprex, Inc. share-based payment arrangement, accelerated cost for the quarter ending 2020-06-30 was $1.50M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month |
|---|---|
| 2020-06-30 | $1.50M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |